The HealthTech Venture Network is proud to welcome founder & CEO of WatchRx, Inc. – Jayanthi Narasimhan – to our 2017 Conference line up, as speaker on our “How Innovating Tech with Patient Advocates Can Benefit Business” panel. Held from 1:30 p.m. – 2:30 p.m., this moderated panel seeks to illustrate why patient advocacy should be a business priority for all healthcare technology companies. This vision is shared through the stories and perspectives of those who practice it every day.
Narasimhan is a serial entrepreneur and award winning innovator with 20+ years of executive leadership.
She is a subject matter expert on telecommunications and has delivered several sophisticated software solutions for Enterprise and Telecom industry that satisfy diverse technology requirements. She is a dynamic leader with a demonstrated history of building successful, top tier teams in cutting edge technology and has worked in many early stage startup companies. During her career, Narasimhan has developed many innovative products in the telecommunications market that are deployed around the world.
Her current role is with WatchRx, a digital healthcare startup that has developed a smartwatch to help aging seniors lead a healthy, independent life and an app for caregivers to get real time status of their parents and help reduce their stress.
Narasimhan has received many awards, particularly in the following regard:
2017 Top Innovators For Aging Market by AARP & Medcity News
2016 Women to Watch in Science & Technology Award by Boston Business Journal
2016 SBANE Innovation Awards Finalist for the WatchRx solution (Top 20 among 190 nominations)
2016 WatchRx WON Google – Boston scientific Sponsored Connected Patient Challenge
2016 Outstanding Women of the Year , Excellence in Business and eldercare from India New England News
Register now for a day of innovation and progressive healthtech discussion with a spotlight on female entrepreneurs in the industry. Early Bird tickets available until September 1st and General Admission on sale until October 2nd.